Figure 1 (Alendronate Fig1)
Alendronate Sodium Tablet
Product Images NDC 50090-5677
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 50090-5677). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2 (Alendronate Fig2)
This text provides the results of studies conducted on the effects of Alendronate 10 mg/day in the treatment of postmenopausal women with osteoporosis. The results are presented in the form of the mean percentage increase of Bone Mineral Density (BMD) relative to placebo, along with standard error (SE), values for the lumbar spine, femoral neck, and trochanter regions. The BMD increased by 12% in three years.*
Figure 3 (Alendronate Fig3)
This is a graph showing the effect of Alendronate 10 mg/day versus a placebo on Lumbar Spine BMD Percent Change From Baseline in postmenopausal women with Osteoporosis. The study was a multinational one and lasted for 36 months. The graph shows that there was a significant increase in BMD percentage for the group that was treated with Alendronate 10 mg/day compared to the placebo group.*
Figure 4 (Alendronate Fig4)
Figure 5 (Alendronate Fig5)
Figure 6 (Alendronate Fig6)
Chemical Structure (Alendronate Str)
Label Image (Lbl500905677)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
